Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Significant Increase in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 49,270 shares, a growth of 78.9% from the November 30th total of 27,540 shares. Based on an average daily volume of 146,092 shares, the days-to-cover ratio is currently 0.3 days. Currently, 2.7% of the company’s shares are sold short. Currently, 2.7% of the company’s shares are sold short. Based on an average daily volume of 146,092 shares, the days-to-cover ratio is currently 0.3 days.

Bluejay Diagnostics Stock Down 3.0%

NASDAQ BJDX opened at $0.68 on Tuesday. Bluejay Diagnostics has a fifty-two week low of $0.63 and a fifty-two week high of $10.20. The business has a 50 day moving average price of $1.43 and a two-hundred day moving average price of $1.58. The stock has a market cap of $1.23 million, a PE ratio of -0.01 and a beta of 0.62.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its earnings results on Friday, November 7th. The company reported ($1.01) EPS for the quarter.

Analysts Set New Price Targets

A number of brokerages have weighed in on BJDX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Monday, December 22nd. Wall Street Zen upgraded shares of Bluejay Diagnostics to a “sell” rating in a report on Saturday, November 1st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.